Tom Lazenby: Accelerating Rare Disease Drug Development Through MHRA’s Investigational Marketing Authorisation
Tom Lazenby, Founder and CEO at Mayet, shared on LinkedIn:
”The MHRA wants to compress rare disease drug development by ten to twelve years.
The mechanism is a single authorisation that combines trial approval with a progressive route to marketing authorisation.
It is called an Investigational Marketing Authorisation.
Announced 21 May 2026. Consultation open until 30 July.
What the framework actually proposes:
- Rolling data submissions and modular assessments rather than a single dossier
- Adaptive trial designs as a default option, including basket and umbrella studies
- Acceptance of surrogate endpoints where conventional endpoints are not feasible
- Technology-agnostic across gene therapies, ATMPs, and repurposed medicines
The line in the announcement that matters most for sponsors and CROs running rare disease trials is not the speed.
It is this:
‘Structured post-authorisation evidence generation for safety, quality and efficacy.’
A faster pathway in does not mean a lighter regulatory expectation out.
The framework pairs the streamlined approval with continuous, structured evidence generation that runs through to post-authorisation.
This is the same principle that lives inside ICH E6(R3) for trial conduct.
Sponsor accountability does not end at submission.
It continues through the whole lifecycle, and the evidence has to be available, not assembled.
If you are running rare disease trials in the UK, three things to think about this week:
- Whether your study evidence trail can support modular assessment rather than dossier submission
- Whether your vendor oversight programme can demonstrate ongoing performance, not point-in-time qualification
- Whether your post-trial evidence generation is a continuous process or a closing activity
The consultation is open.
The MHRA wants input by 30 July.”
Stay updated with Hemostasis Today.
-
May 25, 2026, 22:15Cedric Hermans: What Is Still To Be Discovered and To Be Redefined in The Treatment of Haemophilia A?
-
May 25, 2026, 16:27Gashaw Arega: Advancing Bleeding Disorders Care in Africa
-
May 25, 2026, 16:20Ai Phi Thuy Ho: Varicose Veins Show How Blood Flow Inside the Body Affects What You See on the Skin
-
May 25, 2026, 16:11Ashraf Ali Alsmadi: Recognizing the Difference Between Air Embolism and Pulmonary Embolism
-
May 25, 2026, 16:07Jeanett Mphume: Lymphedema and the Importance of Early Diagnosis
-
May 25, 2026, 15:53Nicolas Nesseler: Do We Overlook Factor XIII Deficiency in VA-ECMO Patients?
-
May 25, 2026, 15:47Wadha Al-Muftah: WHO Adopts Landmark Resolution on Precision Medicine
-
May 25, 2026, 15:43Robert Brown: Evidence-Based Management of Obstetric Hemorrhage
-
May 25, 2026, 15:31Tagreed Alkaltham: Beyond the Blood Bank – How Strong Systems Save Lives Before Emergencies Begin